Biogen Idec, Inc. (Massachusetts) (BIIB)'s Commitment to MS Demonstrated Through Significant Scientific Data Being Presented at the 28th ECTRIMS  
10/10/2012 8:51:21 AM

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) will have extensive data from the company’s leading multiple sclerosis (MS) franchise presented during the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France, October 10 – 13. Fifty-three poster and platform presentations will further showcase Biogen Idec’s commitment to advancing the treatment of MS and improving the lives of people living with the disease around the world.